- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT05484622
Study of Vorasidenib and Pembrolizumab Combination in Recurrent or Progressive Enhancing IDH-1 Mutant Glioma
A Phase 1, Safety Lead-In and Randomized, Open-label, Perioperative Study of Vorasidenib in Combination With Pembrolizumab in Subjects With Recurrent or Progressive Enhancing IDH-1 Mutant Glioma
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
The study is divided into 2 phases, a Safety Lead-In phase and a randomized perioperative phase. In the Safety Lead-In Phase, the recommended combination dose (RCD) of vorasidenib will be determined. In the Randomized Perioperative Phase, the Lymphocytes infiltration in tumors will be evaluated following pre-surgical treatment with vorasidenib and pembrolizumab combination, compared to untreated control tumors. Prior to surgery, participants will be randomized to receive vorasidenib at the RCD in combination with pembrolizumab, or vorasidenib only, or no treatment (untreated control group). Following surgery, participants will have the option to receive treatment with vorasidenib in combination with pembrolizumab in 21-day cycles.
Study treatment will be administered until participant experiences unacceptable toxicity, disease progression, or other discontinuation criteria are met.
Study Type
Enrollment (Estimated)
Phase
- Phase 1
Contacts and Locations
Study Contact
- Name: Institut de Recherches Internationales Servier Clinical Studies Department
- Phone Number: +33 1 55 72 43 66
- Email: scientificinformation@servier.com
Study Locations
-
-
California
-
Los Angeles, California, United States, 90095
- Recruiting
- University of California, Los Angeles (Site: 840113)
-
Contact:
- Email: shwiles@mednet.ucla.edu
-
San Francisco, California, United States, 94013
- Recruiting
- University of California, San Francisco (Site: 840149)
-
Contact:
-
-
Florida
-
Miami, Florida, United States, 33136
- Recruiting
- University of Miami (Site: 840129)
-
Contact:
- Email: yxp303@med.miami.edu
-
-
Illinois
-
Chicago, Illinois, United States, 60045
- Recruiting
- Northwestern University (Site: 840123)
-
Contact:
-
-
Massachusetts
-
Boston, Massachusetts, United States, 02114
- Recruiting
- Massachusetts General Hospital (Site: 840104)
-
Contact:
- Email: lmhibyan@mgb.org
-
Boston, Massachusetts, United States, 02215
- Recruiting
- Dana-Farber Cancer Institute (Site: 840139)
-
Contact:
- Email: Patrick_wen@dfci.harvard.edu
-
-
New York
-
New York, New York, United States, 10017
- Recruiting
- Memorial Sloan Kettering Cancer Center (Site: 840117)
-
Contact:
- Email: KeithN@mskcc.org
-
-
North Carolina
-
Durham, North Carolina, United States, 27705
- Recruiting
- Duke University (Site: 840110)
-
Contact:
- Email: dukebrain1@dm.duke.edu
-
-
Texas
-
Houston, Texas, United States, 77030
- Recruiting
- MD Anderson Cancer Center (Site: 840102)
-
Contact:
- Email: Egachimova@mdanderson.org
-
Contact:
- Email: hsal@mdanderson.org
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Have Karnofsky Performance Status (KPS) of ≥ 70%.
- Have expected survival of ≥ 3 months.
- Have histologically confirmed Grade 2 or Grade 3 astrocytoma (per the 2016 or 2021 World Health Organization [WHO] Classification of Tumors of the central nervous system)
- Have documented IDH1-R132H gene mutation and for Astrocytomas: Absence of 1p19q co-deletion (i.e., exclusion of combined whole-arm deletions of 1p and 19q) and/or documented loss of nuclear ATRX expression or ATRX mutation by local testing. For Oligodendrogliomas: Presence of 1p19q co-deletion (i.e., combined whole-arm deletions of 1p and 19q) by local testing.
- Have measurable, magnetic resonance imaging (MRI)-evaluable, unequivocal contrast enhancing disease as determined by institution radiologist/Investigator at Screening on either 2D T1 post-contrast weighted images or 3D T1 post-contrast weighted images. Per mRANO criteria, measurable lesion is defined as at least 1 enhancing lesion measuring ≥ 1 cm x ≥ 1 cm.
- Have recurrent or progressive disease and received prior treatment with chemotherapy, radiation, or both.
- Surgical resection is indicated for treatment, but surgery is not urgently indicated (e.g., for whom surgery within the next 6-9 weeks is appropriate). (NOTE: This criterion only applies to participants enrolled in the perioperative phase of the study. Participants in the Safety Lead-In should not require surgery).
Exclusion Criteria:
- Have received prior systemic anti-cancer therapy within 1 month of the first dose of IMP, radiation within 12 months of the first dose of IMP, or an investigational agent < 14 days prior to the first dose of IMP. In addition, the first dose of IMP should not occur before a period of ≥ 5 half-lives of the investigational agent has elapsed.
- Have received 2 or more courses of radiation.
- Have received any prior treatment with an isocitrate dehydrogenase (IDH) inhibitor; anti-programmed cell death 1 (PD1), anti-programmed cell death ligand 1 (PD-L1), or anti-PD-ligand 2 (L2) agent, or with an agent directed to another stimulatory or co-inhibitory T-cell receptor (e.g., CTLA-4, OX 40, CD137); any other checkpoint inhibitor; bevacizumab; or any prior vaccine therapy.
Note: Other inclusion and exclusion criteria may apply.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Sequential Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Safety Lead-In Phase: Vorasidenib + Pembrolizumab
Participants will receive vorasidenib orally, once daily (QD) in combination with pembrolizumab 200 mg intravenous (IV) infusion, once every 3 weeks (Q3W) in each 21-day cycle until disease progression, unacceptable toxicity or other discontinuation criteria are met.
|
Administered orally as tablets.
Other Names:
Administered as IV infusion.
Other Names:
|
Experimental: Randomized Perioperative Phase: Vorasidenib + Pembrolizumab
Participants will receive vorasidenib recommended combination dose (RCD) determined in the Safety Lead-in phase, orally, QD from Day 1 to 28 in combination with pembrolizumab 200 mg IV infusion, Q3W on Days 1 and 22 of a 28-day cycle prior to surgery.
|
Administered orally as tablets.
Other Names:
Administered as IV infusion.
Other Names:
|
Experimental: Randomized Perioperative Phase: Vorasidenib Only
Participants will receive vorasidenib orally, QD from Day 1 to 28 of a 28-day cycle prior to surgery.
|
Administered orally as tablets.
Other Names:
|
No Intervention: Randomized Perioperative Phase: Untreated Control Group
Participants will not receive any treatment prior to surgery.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Safety Lead-in Phase: Percentage of Participants With Dose-limiting Toxicities (DLTs)
Time Frame: First 21 days of dosing (Cycle 1) in safety lead-in phase
|
First 21 days of dosing (Cycle 1) in safety lead-in phase
|
|
Percentage of Participants With Adverse Events (AEs) and Serious Adverse Events (SAEs)
Time Frame: approximately up to 19 months
|
approximately up to 19 months
|
|
Percentage of Tumor-infiltrating Lymphocyte (TIL) Cells in Surgically Resected Tumors Following Treatment With Vorasidenib + Pembrolizumab Compared to Untreated Control Tumors
Time Frame: approximately 2 months
|
TIL is defined as the percentage of tumor-infiltrating lymphocyte cells on a logarithmic scale.
|
approximately 2 months
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Overall Survival (OS)
Time Frame: Up to approximately 55 months
|
Overall survival is defined as the time from the date of first dose (in Safety Lead-in) or first postoperative dose (in randomized perioperative phase) to the date of death due to any cause.
|
Up to approximately 55 months
|
AUC: Area Under the Plasma Concentration-Time Curve of Vorasidenib
Time Frame: approximately 16 months
|
approximately 16 months
|
|
Cmax: Maximum Observed Plasma Concentration of Vorasidenib
Time Frame: approximately 16 months
|
approximately 16 months
|
|
Concentration of 2-hydroxygluarate (2-HG) in Surgically Resected Tumors
Time Frame: approximately 2 months
|
approximately 2 months
|
|
Concentration of Vorasidenib in Surgically Resected Tumors
Time Frame: approximately 2 months
|
approximately 2 months
|
|
Clinical Activity Associated With Vorasidenib in Combination With Pembrolizumab According to Modified Response Assessment in Neuro-oncology (mRANO) Criteria
Time Frame: Up to approximately 16 months
|
Up to approximately 16 months
|
|
Time to response
Time Frame: Up to approximately 55 months
|
Defined as the time from the date of first dose (in Safety Lead-In) or the date of first postoperative dose (in randomized perioperative phase) to the date of first documented objective response as assessed by the Investigator per Modified Response Assessment in Neuro-oncology (mRANO) criteria.
|
Up to approximately 55 months
|
Collaborators and Investigators
Collaborators
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Estimated)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
- Neoplasms by Histologic Type
- Neoplasms
- Neoplasms, Glandular and Epithelial
- Glioma
- Neoplasms, Neuroepithelial
- Neuroectodermal Tumors
- Neoplasms, Germ Cell and Embryonal
- Neoplasms, Nerve Tissue
- Astrocytoma
- Molecular Mechanisms of Pharmacological Action
- Antineoplastic Agents
- Antineoplastic Agents, Immunological
- Immune Checkpoint Inhibitors
- Pembrolizumab
Other Study ID Numbers
- CL1-95032-005
- MK-3475-B39 (Other Identifier: Merck Sharp & Dohme LLC)
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
IPD Plan Description
Qualified scientific and medical researchers can request access to anonymized patient-level and study-level clinical trial data.
Access can be requested for all interventional clinical studies:
- Used for Marketing Authorization (MA) of medicines and new indications approved after 1 January 2014 in the European Economic Area (EEA) or the United States (US).
- Where Servier is the Marketing Authorization Holder (MAH). The date of the first MA of the new medicine (or the new indication) in one of the EEA Member States will be considered for this scope.
In addition, access can be requested for all interventional clinical studies in patients:
- Sponsored by Servier
- With a first patient enrolled as of 1 January 2004 onwards
- for New Chemical Entity or New Biological Entity (new pharmaceutical form excluded) for which development has been terminated before any Marketing authorization (MA) approval.
IPD Sharing Time Frame
IPD Sharing Access Criteria
IPD Sharing Supporting Information Type
- STUDY_PROTOCOL
- SAP
- ICF
- CSR
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Astrocytoma
-
St. Jude Children's Research HospitalRecruitingGlioma | Ganglioglioma | Pleomorphic Xanthoastrocytoma | Diffuse Astrocytoma | Pilocytic Astrocytoma | Optic Pathway Glioma | Pilomyxoid AstrocytomaUnited States
-
National Cancer Institute (NCI)CompletedRecurrent Childhood Ependymoma | Childhood Infratentorial Ependymoma | Childhood Supratentorial Ependymoma | Recurrent Childhood Cerebellar Astrocytoma | Recurrent Childhood Cerebral Astrocytoma | Recurrent Childhood Subependymal Giant Cell Astrocytoma | Childhood Mixed Glioma | Childhood Oligodendroglioma and other conditionsUnited States, Canada, Australia
-
Erik MittraNational Cancer Institute (NCI)TerminatedUntreated Childhood Brain Stem Glioma | Adult Anaplastic Ependymoma | Adult Anaplastic Oligodendroglioma | Adult Diffuse Astrocytoma | Adult Giant Cell Glioblastoma | Adult Glioblastoma | Adult Gliosarcoma | Adult Mixed Glioma | Adult Oligodendroglioma | Adult Pilocytic Astrocytoma | Adult Pineal Gland Astrocytoma and other conditionsUnited States
-
National Cancer Institute (NCI)CompletedAdult Anaplastic Astrocytoma | Adult Anaplastic Oligodendroglioma | Adult Diffuse Astrocytoma | Adult Giant Cell Glioblastoma | Adult Glioblastoma | Adult Gliosarcoma | Adult Mixed Glioma | Adult Pilocytic Astrocytoma | Adult Pineal Gland Astrocytoma | Recurrent Adult Brain Tumor | Adult Subependymal Giant...United States
-
National Cancer Institute (NCI)Active, not recruitingAstrocytoma, IDH-Mutant, Grade 2 | Astrocytoma, IDH-Mutant, Grade 3United States
-
Washington University School of MedicineCompletedAstrocytoma, Grade III | Astrocytoma, Grade IV | Grade IV Astrocytoma | Grade III AstrocytomaUnited States
-
National Cancer Institute (NCI)CompletedChildhood High-grade Cerebellar Astrocytoma | Childhood High-grade Cerebral Astrocytoma | Recurrent Childhood Anaplastic Astrocytoma | Recurrent Childhood Anaplastic Oligoastrocytoma | Recurrent Childhood Anaplastic Oligodendroglioma | Recurrent Childhood Cerebellar Astrocytoma | Recurrent Childhood... and other conditionsUnited States, Canada
-
Mayo ClinicNational Cancer Institute (NCI)Active, not recruitingAdult Anaplastic Astrocytoma | Adult Anaplastic Ependymoma | Adult Anaplastic Oligodendroglioma | Adult Diffuse Astrocytoma | Adult Ependymoma | Adult Giant Cell Glioblastoma | Adult Glioblastoma | Adult Gliosarcoma | Adult Mixed Glioma | Adult Myxopapillary Ependymoma | Adult Oligodendroglioma | Adult Pilocytic... and other conditionsUnited States
-
Sidney Kimmel Cancer Center at Thomas Jefferson...Millennium Pharmaceuticals, Inc.CompletedAdult Anaplastic Astrocytoma | Adult Anaplastic Ependymoma | Adult Anaplastic Oligodendroglioma | Adult Diffuse Astrocytoma | Adult Giant Cell Glioblastoma | Adult Glioblastoma | Adult Gliosarcoma | Adult Mixed Glioma | Adult Oligodendroglioma | Adult Pilocytic Astrocytoma | Adult Pineal Gland Astrocytoma | Recurrent... and other conditionsUnited States
-
National Cancer Institute (NCI)CompletedAdult Anaplastic Astrocytoma | Adult Diffuse Astrocytoma | Adult Giant Cell Glioblastoma | Adult Glioblastoma | Adult Gliosarcoma | Adult Mixed Glioma | Adult Oligodendroglioma | Adult Pineal Gland AstrocytomaUnited States
Clinical Trials on Vorasidenib
-
ServierServier Pharmaceuticals, LLCAvailablePathologic Processes | Glioma | Neoplasms | Neoplasms by Histologic Type | Neoplasms, Glandular and Epithelial | Recurrence | Disease Attributes | Neoplasms, Germ Cell and Embryonal | Neoplasms, Neuroepithelial | Neuroectodermal Tumors | Neoplasms, Nerve Tissue
-
Institut de Recherches Internationales ServierCompleted
-
Agios Pharmaceuticals, Inc.CompletedHealthy VolunteersUnited States
-
Institut de Recherches Internationales ServierActive, not recruitingRecurrent Glioma | Grade 2 Glioma | Residual GliomaUnited States, Canada, Spain, Italy, United Kingdom, Switzerland, Israel, Japan, Netherlands, Germany, France
-
Katy Peters, MD, PhDServierNot yet recruitingLow Grade Glioma of BrainUnited States
-
Galmed Medical ReserchHillel Yaffe Medical Center; Hadassah Medical Organization; Tel-Aviv Sourasky... and other collaboratorsCompletedStudy of Aramchol in Patients With Fatty Liver Disease or Nonalcoholic Steatohepatitis (Aramchol003)Metabolic Syndrome | Nonalcoholic Steatohepatitis | Non-Alcoholic Fatty Liver DiseaseIsrael
-
Servier Bio-Innovation LLCInstitut de Recherches Internationales ServierRecruiting